Trials / Completed
CompletedNCT05073666
Prevalence and Risk Factors of Chronic Thrombo-embolic Disease After a Pulmonary Embolism Event
Prevalence and Risk Factors of Chronic Thrombo-embolic Disease After a Pulmonary Embolism Event The PACTE Registry
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 123 (actual)
- Sponsor
- Centre Hospitalier Universitaire de Nice · Academic / Other
- Sex
- All
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
Venous thromboembolic disease (VTE) is a common clinical entity whose two manifestations are deep vein thrombosis (DVT) and pulmonary embolism (PE). After an acute PE, almost half of the patients complain residual dyspnea, despite well-conducted curative anticoagulation. Some will present persistent defects on lung scan-scintigraphy, without pulmonary hypertension. This condition defines Chronic-Thrombo-Embolic Disease(CTED). The prevalence of CTED after PE is poorly known as are its risk factors. The primary objective is to determine the prevalence of CTED at 3 or 6 months, depending on the provoked or unprovoked character, after a PE. The secondary objectives are: * To determine the potential risk factors for the occurrence of CTED. * To look for an association between the persistence of DVT and the occurrence of CTED. * To look for an association between the diagnosis of CTED and PE recurrence during the 12-month follow-up. * To determine the diagnostic performance of the clinician alone compared to the lung scintigraphy (gold standard) for the diagnosis of CTED. * To compare the impact on the quality of life (QoL) with or without CTED. * To determine the correlation between impaired QoL and the degree of residual obstruction on lung scintigraphy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | NO INTERVENTION | NO INTERVENTION |
Timeline
- Start date
- 2021-01-01
- Primary completion
- 2023-02-03
- Completion
- 2023-02-03
- First posted
- 2021-10-11
- Last updated
- 2025-03-06
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05073666. Inclusion in this directory is not an endorsement.